MDT

88.48

+1.88%↑

A

120.48

+4.67%↑

VEEV

159.5

+2.37%↑

HQY

80.5

+3.11%↑

TLRY

6.99

+8.37%↑

MDT

88.48

+1.88%↑

A

120.48

+4.67%↑

VEEV

159.5

+2.37%↑

HQY

80.5

+3.11%↑

TLRY

6.99

+8.37%↑

MDT

88.48

+1.88%↑

A

120.48

+4.67%↑

VEEV

159.5

+2.37%↑

HQY

80.5

+3.11%↑

TLRY

6.99

+8.37%↑

MDT

88.48

+1.88%↑

A

120.48

+4.67%↑

VEEV

159.5

+2.37%↑

HQY

80.5

+3.11%↑

TLRY

6.99

+8.37%↑

MDT

88.48

+1.88%↑

A

120.48

+4.67%↑

VEEV

159.5

+2.37%↑

HQY

80.5

+3.11%↑

TLRY

6.99

+8.37%↑

Search

IQVIA Holdings Inc

Avatud

SektorTervishoid

174.75 3.19

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

169.6

Max

175.99

Põhinäitajad

By Trading Economics

Sissetulek

182M

514M

Müük

264M

4.4B

P/E

Sektori keskmine

21.803

66.418

Kasumimarginaal

11.778

Töötajad

93,000

EBITDA

1B

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+34.18% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

5. mai 2026

Turustatistika

By TradingEconomics

Turukapital

-10B

29B

Eelmine avamishind

171.56

Eelmine sulgemishind

174.75

Uudiste sentiment

By Acuity

50%

50%

154 / 348 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bullish Evidence

IQVIA Holdings Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

13. apr 2026, 23:25 UTC

Uudisväärsed sündmused

Westpac Expects Higher Loan Losses as Iran Conflict Slows Australian Economy -- Update

13. apr 2026, 22:45 UTC

Uudisväärsed sündmused

Westpac Expects Higher Loan Losses as Iran Conflict Slows Australian Economy

13. apr 2026, 18:03 UTC

Tulu

Louis Vuitton Owner Logs Weak Sales as Middle East War Takes Toll -- 2nd Update

13. apr 2026, 23:58 UTC

Tulu

Review & Preview: Earnings Time -- Barrons.com

13. apr 2026, 23:49 UTC

Market Talk

Nikkei May Rise After Overnight Gains on Wall Street -- Market Talk

13. apr 2026, 23:33 UTC

Market Talk
Uudisväärsed sündmused

Gold Edges Higher Amid Dollar Weakness -- Market Talk

13. apr 2026, 23:20 UTC

Market Talk

Uranium Stocks Seen Benefiting From Energy Security Concerns -- Market Talk

13. apr 2026, 23:01 UTC

Tulu

Aura: Capex Guidance Revised From $111M and $130M to New Range of $262M and $314M >AURA33.SA.BR

13. apr 2026, 23:01 UTC

Tulu

Aura Minerals: Announces Update to Capex Guidance Including Construction of the Era Dorada Project

13. apr 2026, 23:01 UTC

Tulu

Aura: Will Update Cap Expenditure Guidance to Include the Project's Construction Phase >AURA33.SA.BR

13. apr 2026, 22:21 UTC

Omandamised, ülevõtmised, äriostud

Chevron Swaps Offshore Gas Stakes to Boost Venezuelan Heavy-Oil Footprint -- Update

13. apr 2026, 21:53 UTC

Tulu

MarketWise, Inc.: Affirms FY 2026 Guidance, Including Div Target to Class A Hldrs of $1.80 per Shr

13. apr 2026, 21:53 UTC

Tulu

MarketWise, Inc.: Paid Subscribers Were 381,000 at March 31 Compared to 374,000 at Dec 31, 2025, Active Free Subscribers Were 2.0M at March 31 >MKTW

13. apr 2026, 21:53 UTC

Tulu

MarketWise, Inc.: 1Q Billings Increased Approximately 15% Yr-over-Yr to Approximately $81M

13. apr 2026, 21:53 UTC

Tulu

MarketWise, Inc.: Preliminary Selected Unaudited 1Q Paid Subscribers Returning to Growth

13. apr 2026, 21:26 UTC

Uudisväärsed sündmused

U.S. Oil Blockade Is Set to Boost American Exports -- and Prices at the Pump -- WSJ

13. apr 2026, 21:23 UTC

Tulu

Johnson & Johnson Earnings: Oncology Powers Growth, but Talc Lawsuits Persist -- Barrons.com

13. apr 2026, 21:16 UTC

Tulu

Goldman Sachs Reports Record Quarter in Banking and Trading -- 4th Update

13. apr 2026, 20:50 UTC

Market Talk
Uudisväärsed sündmused

Basic Materials Roundup: Market Talk

13. apr 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

13. apr 2026, 20:34 UTC

Tulu

Victory Capital: 1Q Long-Term AUM Net Flows of -$457M >VCTR

13. apr 2026, 20:34 UTC

Tulu

Victory Capital: March Avg Total AUM Was $315.3B, Avg Other Assets $3.2B, Avg Total Client Assets $318.5B >VCTR

13. apr 2026, 20:34 UTC

Tulu

Victory Capital Holdings, Inc.: Total Assets Under Management of $309.8B, Other Assets $3.3B, Total Client Assets of $313.1B as of March 31 >VCTR

13. apr 2026, 19:59 UTC

Market Talk

Canada Consumers Sour Prior to Big Energy-Price Jump -- Market Talk

13. apr 2026, 19:50 UTC

Market Talk
Uudisväärsed sündmused

Oil Futures Pull Back From Highs on Hopes for Talks -- Market Talk

13. apr 2026, 19:27 UTC

Market Talk
Uudisväärsed sündmused

Correction to Precious Metals Market Talk on April 9

13. apr 2026, 19:14 UTC

Market Talk

U.S. Natural Gas Futures Settle Lower on Mild Weather -- Market Talk

13. apr 2026, 18:59 UTC

Market Talk
Uudisväärsed sündmused

Fed's Goolsbee: Don't Be Surprised If Consumer Confidence Sours -- Market Talk

13. apr 2026, 18:59 UTC

Market Talk
Uudisväärsed sündmused

Fed's Goolsbee: Oil Shows People Expect Short Term Conflict in Iran -- Market Talk

13. apr 2026, 18:43 UTC

Market Talk

Precious Metals Lose Ground as U.S. Blockade in Hormuz Gets Underway -- Market Talk

Võrdlus sarnastega

Hinnamuutus

IQVIA Holdings Inc Prognoos

Hinnasiht

By TipRanks

34.18% tõus

12 kuu keskmine prognoos

Keskmine 224.54 USD  34.18%

Kõrge 255 USD

Madal 185 USD

Põhineb 16 Wall Streeti analüütiku instrumendi IQVIA Holdings Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

16 ratings

14

Osta

2

Hoia

0

Müü

Tehniline skoor

By Trading Central

150.68 / 153.45Toetus ja vastupanu

Lühikene perspektiiv

Bullish Evidence

Keskpikk perspektiiv

Neutral Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

154 / 348 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest IQVIA Holdings Inc

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE; and a strategic collaboration with NVIDIA Corporation. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.
help-icon Live chat